Clinical trials: Mucormycosis
Hemifacial Microsomia, Mucormycosis
Clinical Evaluation of Patient-Specific 3D-Printed Titanium Implants for Facial Reconstruction.
This clinical study aims to evaluate the effectiveness of patient-specific 3D-printed titanium facial implants in the reconstruction and aesthetic correction of facial defects.
- Conditions
- Hemifacial Microsomia, Mucormycosis, Oral Squamous Cell Carcinoma, Microgenia
- Trial name
- 3DFACE (NCT07654647)
- Testing
- Patient-specific titanium implants for facial reconstruction
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Latakia University
Maxillary Defect Reconstruction, Atrophic Edentulous Maxilla
Evaluation of Accuracy of Three-Dimensionally Guided Zygomatic Implant Installation
This study was conducted at the Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tanta University. A prospective non-controlled clinical study was performed on ten patients with compromised zygomaticomaxillary…
- Trial name
- NCT07463469
- Testing
- zygomatic implant installation using custamized bone supported surgical guide
- Where
- Egypt
- Volunteers
- 10 people
- Sponsor
- Tanta University
Invasive Aspergillosis, Mucormycosis
A Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom).
- Trial name
- PRISMA (NCT04550936)
- Testing
- Isavuconazole
- Where
- 15 sites in France, Germany and 3 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Mycoses
PK/PD Study of Posaconazole for Empiric Treatment of Invasive Fungal Infections in Neutropenic Patients or Treatment of Refractory Invasive Fungal Infections (Study P01893)
This phase II study will be conducted to: 1. evaluate the pharmacokinetics, safety, tolerance, and efficacy of different dosing schedules of Posaconazole in immunocompromised hosts with a variety of refractory invasive fungal…
- Trial name
- NCT00034671
- Testing
- Posaconazole oral suspension
- Volunteers
- 98 people
- Sponsor
- Merck Sharp & Dohme LLC
Covid-19
Characterization of Fungal Infections in COVID-19 Infected and Mechanically Ventilated Patients in ICU
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
- Trial name
- MY-CO-VID (NCT04368221)
- Where
- 22 sites in France
- Volunteers
- 576 people
- Sponsor
- Rennes University Hospital
Mucormycosis
Mucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
To collect data and samples from participants with cancer who also have invasive mucormycosis, invasive aspergillosis, bacterial pneumonia, or a risk for fungal infection.
- Trial name
- NCT06878144
- Testing
- Mucormycosis
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Aspergillosis Invasive, Mucormycosis
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
The goal of this clinical trial is to learn the plasma concentration of isavuconazole in pediatric patients. It will also learn about the relationship of isavuconazole plasma concentrations to efficacy and safety in pediatric…
- Trial name
- NCT06440915
- Testing
- Theraputic drug monitoring, Isavuconazole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Children's Medical Center
Deep Mycosis
Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis
The objective of this study is to investigate the safety and efficacy of administering 372.6 mg of AK1820 (isavuconazonium sulfate) intravenously or orally to adult Japanese patients with deep mycosis.
- Trial name
- NCT03471988
- Testing
- AK1820, Voriconazole
- Where
- 33 sites in Japan
- Volunteers
- 103 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Mucormycosis
Rehabilitation With an Obturator in Maxillary Defects
During the COVID-19 pandemic, there was a lot of reporting of COVID-19-associated mucormycosis cases. Managing this condition posed a new challenge to clinicians.
- Trial name
- NCT06515743
- Testing
- Obturator Prosthetic Rehabilitation
- Where
- Egypt
- Volunteers
- 42 people
- Sponsor
- Menoufia University
Pulmonary Mucormycosis
Efficacy and Safety of Systematic Therapy and Bronchoscopic Interventional Treatment for Pulmonary Mucormycosis
Evaluation of the effectiveness and safety of transbronchoscopic local precision infusion of amphotericin B + transoral nebulized inhalation of amphotericin B + transbronchoscopic interventional debridement + liposomal…
- Trial name
- NCT06495905
- Testing
- transbronchoscopic interventional debridement
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Mucormycosis, Hematologic Malignancies
Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China
The project intends to carry out a retrospective study on the epidemiology, predisposing factors, clinical manifestations, diagnosis, treatment, prognosis and economic burden of mucormycosis in a Chinese single-center allogeneic…
- Conditions
- Mucormycosis, Hematologic Malignancies, COVID-19
- Trial name
- NCT06900114
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pulmonary Mucormycosis
Antifungal Drugs in Pulmonary Mucormycosis
Pulmonary mucormycosis (PM) poses a substantial clinical challenge, particularly among immunocompromised patients. The aim of the study is to determine the effectiveness and safety of administering AmBisome at a dose of…
- Trial name
- NCT06756191
- Testing
- Combination therapy group, Liposomal Amphotericin B
- Volunteers
- 312 people
- Sponsor
- Bin Cao
Mucormycosis; Rhinocerebral (Etiology), Post COVID-19 Condition, Unspecified
Post-COVID-19 Mucormycosis in Critical Care
Background: Mucormycosis is a life-threatening opportunistic fungal infection. Despite mucormycosis having existed for decades, it has gained notice of its widespread in many parts of the world during the second wave of the…
- Trial name
- NCT05911035
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- Zagazig University
Zygomycosis
Pilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment
Evaluation after 4 weeks of treatment or at end of treatment if it occurs before. Efficacy will be defined as objective responses; complete and partial response.
- Trial name
- AMBIZYGO (NCT00467883)
- Testing
- Liposomal Amphotericin B
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Aspergillosis, Mucormycosis
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
The purpose of this study is to observe safety and effectiveness of Cresemba in patients with invasive Aspergillosis or invasive Mucormycosis in Korea during the post-marketing surveillance period as required by Ministry of Food…
- Trial name
- NCT04744454
- Testing
- Isauvuconazole group
- Where
- South Korea
- Volunteers
- 94 people
- Sponsor
- Pfizer
Mucormycosis
Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
Background: Mucormycosis is a serious but rare fungal infection that requires rapid and effective treatment. The two main antifungal medicines used are amphotericin B and isavuconazole.
- Trial name
- AIM (NCT07191756)
- Testing
- Amphotericin B, Isavuconazole
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Qiu Ye
Fungal Infection, ICU Acquired Weakness
Emerging Invasive Fungal Infections in Critically Ill Patients
Rationale: Beside Candida and Aspergillus, emerging invasive fungal infections (EIFIs) are increasing in intensive care setting and are associated with high morbidity and mortality.
- Trial name
- EIFI (NCT04647539)
- Where
- France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Montpellier
Immunocompromised Host, Invasive Pulmonary Fungal Infection
Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis
Background: Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus and Zygomycetes, but these causes are often difficult for a doctor to diagnose.
- Conditions
- Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
- Trial name
- NCT00923832
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
COVID-19, Mucormycosis
Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.
- Trial name
- NCT05097664
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Isfahan University of Medical Sciences